Moran Rachel, Beatty Stephen, Stack Jim, O'Halloran Aisling M, Feeney Joanne, Akuffo Kwadwo O, Peto Tunde, Kenny Rose Anne, Nolan John M
a Macular Pigment Research Group, Nutrition Research Centre Ireland, School of Health Science, Waterford Institute of Technology , Waterford , Ireland.
b The Irish Longitudinal Study on Ageing, Department of Medical Gerontology , Trinity College , Dublin , Ireland.
Curr Eye Res. 2018 Mar;43(3):383-390. doi: 10.1080/02713683.2017.1403633. Epub 2017 Nov 27.
To investigate plasma lutein (L) and zeaxanthin (Z) concentrations with grading-confirmed and self-reported prevalence of age-related macular degeneration (AMD).
Data collected from a nationally representative prospective cohort study of community-dwelling adults aged 50 years and over in the Republic of Ireland. Participants underwent a computer-assisted personal interview and a center-based health assessment. Plasma concentrations of L and total Z (Z and meso-zeaxanthin [MZ]) were measured by high performance liquid chromatography, and retinal photographs were graded using a version of the AMD International Classification and Grading System. Consumption of supplements containing L and/or Z and/or MZ was recorded as supplement use. Four groups were identified: Group 1 (n = 24): AMD-afflicted and correctly aware; Group 2 (n = 264): AMD-afflicted but unaware; Group 3 (n = 41): AMD-free and incorrectly believed that they were afflicted with the condition; Group 4 (n = 4094): AMD-free and correctly self-reported absence of AMD.
Of 4,423 participants with plasma concentrations of L and Z and gradable retinal photographs, 288 (6.5%) were afflicted with AMD, and 65 (1.5%) self-reported AMD. Controlling for family history and age, the relationship between grading-confirmed AMD and plasma L was positive and significant (p < 0.001). Mean plasma concentrations of L in Group 2 (mean = 0.2162 ± 0.132 µmol) and Group 4 (mean = 0.2040 ± 0.121 µmol/L) were significantly lower than Group 1 (mean = 0.4691 ± 0.0.372 µmol/L) and Group 3 (mean = 0.3176 ± 0.0.235 µmol/L). Supplement use was reported by 41.7% and 17.1% of participants in Groups 1 and 3, respectively, but only 2.7% and 1.9% of participants in Groups 2 and 4, respectively.
A belief that one suffers from AMD, whether justified or not, is associated with supplement use and with higher plasma concentrations of L.
研究血浆叶黄素(L)和玉米黄质(Z)浓度与经分级确认及自我报告的年龄相关性黄斑变性(AMD)患病率之间的关系。
数据来自爱尔兰共和国一项具有全国代表性的针对50岁及以上社区居住成年人的前瞻性队列研究。参与者接受了计算机辅助个人访谈和基于中心的健康评估。采用高效液相色谱法测定血浆L和总Z(Z和内消旋玉米黄质[MZ])的浓度,并使用AMD国际分类和分级系统的一个版本对视网膜照片进行分级。记录含有L和/或Z和/或MZ的补充剂的摄入量作为补充剂使用情况。确定了四组:第1组(n = 24):患有AMD且正确知晓;第2组(n = 264):患有AMD但未意识到;第3组(n = 41):未患AMD但错误地认为自己患有该病;第4组(n = 4094):未患AMD且正确自我报告未患AMD。
在4423名有血浆L和Z浓度及可分级视网膜照片的参与者中,288人(6.5%)患有AMD,65人(1.5%)自我报告患有AMD。在控制家族史和年龄后,经分级确认的AMD与血浆L之间的关系呈正相关且具有显著性(p < 0.001)。第2组(均值 = 0.2162 ± 0.132 µmol)和第4组(均值 = 0.2040 ± 0.121 µmol/L)的血浆L平均浓度显著低于第1组(均值 = 0.4691 ± 0.0.372 µmol/L)和第3组(均值 = 0.3176 ± 0.0.235 µmol/L)。第1组和第3组分别有41.7%和17.1%的参与者报告使用了补充剂,但第2组和第4组分别只有2.7%和1.9%的参与者使用了补充剂。
无论是否有依据,认为自己患有AMD与补充剂使用及较高的血浆L浓度相关。